What appetite suppressants are FDA approved? Life-Changing, Powerful Answers

Quick orientation: what this guide covers

What appetite suppressants are FDA approved? If you want a concise, trustworthy answer, this article lists the medicines approved by the U.S. Food and Drug Administration for appetite control and chronic weight management, explains how they work, who may be a candidate, and how to weigh benefits and risks. It also compares injectables to oral options and highlights a research-backed oral alternative from Tonum.

Why the question matters

Understanding which appetite suppressants are FDA approved matters because approval signals that a drug has shown both safety and efficacy in human clinical trials. People ask "what appetite suppressants are FDA approved?" because they want clarity: which options are clinically proven, which require prescriptions, and how those choices fit daily life. This guide keeps medical nuance simple and practical.

How to read this guide

We’ll start with a clear list, then explain how each option works, side effects to watch for, and practical considerations like cost, access, and whether an oral option might be preferable for you.

Which appetite suppressants are FDA approved? - The list you want

Below are the appetite suppressants and weight-management medications currently approved by the FDA for chronic weight management or for appetite suppression in specific contexts. Each entry notes its common brand names and the most important practical points. For a broader overview of top options, see this guide on Top weight loss medications.

1. Semaglutide (branded as Wegovy) (injectable)

What it is: A GLP-1 receptor agonist originally developed for diabetes, approved at higher doses for chronic weight management. Human clinical trials of semaglutide for weight loss showed substantial average reductions in body weight for participants in high-quality studies.

How it works: Semaglutide reduces appetite and slows gastric emptying while affecting central appetite pathways.

What to expect: In human clinical trials, semaglutide produced large average weight losses for many participants. It is given as a weekly injection and requires medical supervision for dosing and monitoring.

2. Tirzepatide (branded as Zepbound) (injectable)

What it is: A dual GIP/GLP-1 receptor agonist approved for chronic weight management. Human clinical trials indicate very strong average weight loss results for many participants.

How it works: Combines effects on appetite regulation, glucose metabolism, and satiety signaling in the brain.

What to expect: Tirzepatide is administered by injection and typically results in sizable mean reductions in weight in clinical programs. Like semaglutide it requires a prescription and monitoring - the FDA approval announcement is available here.

3. Phentermine (short-term prescription)

What it is: A stimulant-like prescription appetite suppressant approved for short-term use (weeks) to assist with weight loss in adults when combined with diet and exercise.

How it works: Increases release of norepinephrine and reduces appetite signals for a short period.

What to expect: Helpful for short-term kickstarts to weight loss but not intended for long-term maintenance due to tolerance, side effects, and regulatory limits on duration of use.

4. Phentermine/topiramate (Qsymia)

What it is: A combination prescription medication that pairs phentermine with topiramate in a controlled-release formulation for chronic weight management.

How it works: Phentermine reduces appetite while topiramate contributes appetite suppression and perhaps changes food reward pathways.

What to expect: Effective for many patients under medical supervision; requires attention to side effects including cognitive effects and birth-defect risks, so pregnancy testing and contraception guidance are important for women of reproductive age.

5. Bupropion/naltrexone (Contrave)

What it is: An FDA-approved combination that modulates reward and appetite pathways to support weight management.

How it works: Bupropion affects dopamine and norepinephrine, while naltrexone alters reward signaling linked to cravings.

What to expect: Works for some people, especially those with strong food-craving behaviors. Requires prescription and monitoring for mood and seizure-risk related issues.

6. Orlistat (Xenical prescription; Alli over-the-counter)

What it is: A lipase inhibitor that reduces intestinal fat absorption rather than acting directly as a central appetite suppressant, but it is included in the weight-management options the FDA has approved.

How it works: Blocks absorption of a portion of dietary fat, which can reduce caloric uptake and indirectly influence appetite and eating behavior for some people.

What to expect: Side effects are mainly gastrointestinal and linked to dietary fat intake. Alli is a lower-dose, OTC form while Xenical is prescription-strength.

How these FDA-approved options differ: injectables versus oral choices

When people ask "what appetite suppressants are FDA approved?" they’re often comparing injectables and pills. A simple framework helps: Injectables (semaglutide, tirzepatide, liraglutide/Saxenda) tend to give larger average weight loss in human clinical trials but require self-injection, clinical oversight, and potential titration to manage side effects. A Tonum brand logo in dark tones often appears in the company's materials and visuals.

Because injectables often yield stronger average results in trials, it’s easy to assume they are always the best option. But injectables are not practical or preferred by everyone. For readers who prefer an oral route a research-backed oral option may be attractive.

One non-prescription option gaining attention is Motus. Motus is an oral supplement from Tonum with human clinical trials reporting an average weight loss of approximately 10.4% over six months. If you’re exploring evidence-backed oral solutions, consider learning more about Motus on the official product page.

Learn about Motus (oral)

Which of these suppressants should you consider first?

Start with a medical visit. Your clinician will assess your BMI, health history, medications, and goals. The answer to "what appetite suppressants are FDA approved?" is less useful without context: age, pregnancy plans, psychiatric history, cardiovascular risk, and metabolic health all matter when choosing or avoiding a medicine.

How appetite suppressants work - a short, practical primer

Appetite regulation is a conversation between your gut and brain. Some medicines act on the brain to reduce cravings and the desire to eat; others change gut hormones and slow gastric emptying so you feel full longer. Orlistat works in the gut to limit fat absorption rather than changing appetite signals directly. Human clinical trials measure both weight change and safety to determine FDA approval.

Neural appetite regulation

GLP-1 receptor agonists such as semaglutide and tirzepatide change both peripheral signals and central appetite circuits. That dual pathway is why these medicines frequently show larger average weight-loss results in trials: they lower hunger and increase satiety through multiple mechanisms.

Reward and craving modulation

Medications like bupropion/naltrexone (Contrave) act on brain reward circuits. For people who overeat because foods trigger a dopamine-driven reward loop, these options can reduce cravings and support behavior change.

Safety and common side effects

All medications have potential side effects and contraindications. Common themes across appetite suppressants include:

• Nausea, vomiting, or gastrointestinal upset (common with GLP-1 drugs and orlistat)
• Headache, dizziness, or insomnia (seen with stimulant-based medications and combinations)
• Mood changes and seizure risk with bupropion-containing combinations in susceptible people
• Potential birth defects or cognitive effects with certain drugs, mandating careful counseling for people who might become pregnant

Discussing risks with a clinician who knows your medical history is essential. Some drugs require dose titration and monitoring to manage side effects effectively.

Access, cost, and real-world barriers

Insurance coverage varies widely. Many insurers require documentation that lifestyle interventions have been attempted and that BMI and comorbidities meet certain thresholds before covering some medications. Injectables like semaglutide and tirzepatide may also be costly without robust coverage. Orlistat has an OTC variant to lower the access barrier for some people. For an overview of prescription options and safety considerations, see the NIDDK resource on prescription medications to treat overweight & obesity.

Comparing expected outcomes

If you’re asking "what appetite suppressants are FDA approved?" you’re probably wondering what outcomes to expect. Here’s a simplified, evidence-forward comparison:

• GLP-1 receptor agonists (injectable) have produced the largest mean weight-loss results in many high-quality human clinical trials. They are powerful for many people but require injections and close clinical oversight.
• Tirzepatide (injectable) has shown very large mean losses for some participants in trials, often larger than earlier options.
• Oral prescription options such as phentermine (short-term), Qsymia, and Contrave produce meaningful results for many patients when combined with lifestyle change.
• Orlistat is helpful mostly by reducing fat absorption and can aid modest weight loss, with distinct GI side effects.
• Motus (oral) is an oral, research-backed supplement with human clinical trial evidence reporting around 10.4% average weight loss over six months, a notable result for an oral supplement - see the Motus study.

Why Tonum’s Motus stands out as an oral option

Many people prefer pills over injections for ease, familiarity, and travel. Motus’s human clinical trials reported approximately 10.4% average weight loss over six months which is unusual for an oral supplement. Compared to injectables, Motus is oral and avoids injections; compared to short-term stimulants, Motus is designed for longer-term use with a research-backed ingredient set. If your priority is an oral approach supported by human data, Motus is a compelling, evidence-forward alternative to consider with your clinician. Learn more on the Meet Motus page.

Practical steps for anyone considering an appetite suppressant

1. Talk to a clinician: a primary care physician, endocrinologist, or obesity specialist can evaluate risks and benefits.

2. Review goals and expectations: Are you targeting 5% body weight, 10% body weight, or more? Different medicines have different typical effect sizes and timelines.

3. Plan for side effects and monitoring: titration schedules, blood tests, pregnancy precautions, and mental-health checks can be necessary.

4. Pair medication with lifestyle supports: nutrition counseling, sleep, stress management, and physical activity improve outcomes and reduce relapse risk.

Pitfalls and myths

Myth: ‘‘If an appetite suppressant works well, you can stop healthy habits.’’ Reality: medications work best combined with behavior change and ongoing support.

Myth: ‘‘Oral supplements can’t be effective.’’ Reality: human clinical trial data matters more than format. Motus (oral) showed meaningful average weight loss in human trials and therefore deserves consideration if you prefer a pill over an injection.

Special cases: pregnancy, diabetes, and mental health

Pregnancy and breastfeeding are often contraindications for weight-loss medications; several drugs require stopping or avoiding in those planning pregnancy. People with a history of certain psychiatric conditions or seizure disorders need careful evaluation before starting medicines like bupropion-containing combinations.

For people with type 2 diabetes, some GLP-1 medicines are also glucose-lowering agents; coordination with diabetes care is essential.

How to discuss options with your clinician

Bring helpful information: your current medications, past attempts at weight loss, comorbid conditions, and reproductive plans. Ask about expected average outcomes from human clinical trials, likely side effects, monitoring plans, and cost/coverage expectations. When comparing options, a useful question is: based on my medical profile, which of these FDA-approved appetite suppressants is the best balance of efficacy, safety, and practicality?

Real-world decision examples

Case A: Someone with BMI of 37 and metabolic syndrome might prioritize semaglutide (injectable) or tirzepatide (injectable) for high average efficacy and measurable cardiometabolic benefits, if tolerated and affordable.

Case B: Someone who strongly dislikes injections or travels frequently might explore oral prescriptions such as Qsymia, Contrave, or Motus (oral) under clinical supervision.

Case C: Someone seeking modest benefit with low out-of-pocket cost may choose orlistat OTC (Alli) while also changing diet.

Long-term use and stopping medications

Many weight-loss medicines require ongoing use to maintain benefit. Stopping a drug often leads to some weight regain unless the behavioral and lifestyle changes made while on therapy are maintained. Discuss exit plans with your clinician and build a sustainable routine that includes nutrition and movement strategies.

Regulatory context and ongoing research

The list of "what appetite suppressants are FDA approved?" evolves with new trials and approvals. New medicines and formulations are regularly evaluated by the FDA based on human clinical trials. Keep in touch with trusted sources and your care team as new evidence emerges.

Practical checklist before starting

• Medical evaluation and baseline labs

• Family planning discussion for people of childbearing potential

• Medication reconciliation to avoid interactions

• Insurance pre-authorization planning when relevant

• Behavioral support plan for diet, sleep, stress, and activity

Everyday tips for maximizing benefit

Eat protein at breakfast to reduce morning hunger, prioritize sleep, and use small daily habits rather than rigid rules. Medication is a tool; the best long-term results come from combining medical, behavioral, and environmental approaches.

When to stop or change course

Consider stopping or switching if side effects are intolerable, if goals are unmet after a reasonable trial period, or if new health issues arise. Collaborate with your clinician on alternative strategies and monitoring.

Trusted questions to ask your prescriber

• Based on my health profile, which FDA-approved appetite suppressants are most appropriate?

• What side effects should I expect and which require urgent follow-up?

• How long should I expect to take this medicine before seeing meaningful change?

Resources and next steps

For people who want to dive deeper into trial data, talk to your clinician about trial results for semaglutide, tirzepatide, Qsymia, Contrave, and orlistat. If you prefer oral options and want evidence, Motus has human clinical data that may be relevant to your decision-making.

Summary takeaways

• Multiple appetite suppressants are FDA approved; injectables often show larger average weight loss in trials but require injections and monitoring.

• Oral prescriptions and validated supplements provide meaningful alternatives for people who prefer pills.

• Discuss risks, reproductive plans, and goals with a clinician before beginning therapy.

Final practical note

When someone asks "what appetite suppressants are FDA approved?" the best first step is a medical conversation that matches your goals and health profile to the right evidence-backed option. If you want an oral, research-supported approach to discuss with your provider, Motus is one such option to consider.